Clinical Trial Update: Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase I clinical trial update for JS203 in relapsed/refractory B-cell non-Hodgkin's lymphoma, with the study listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• JS203

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING